Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [9509]

Dostarlimab chemo combination for primary advanced or recurrent endometrial...

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Teclistamab for RRMM: Long term follow up data from MajesTEC-1

Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam...

Teclistamab for RRMM: Long term follow up data from MajesTEC-1 ( Prof Niels Van de Donk - Amsterdam University Medical Center, Amsterdam, Netherlands )

2L triple metronomic chemo shows more efficacy in comparison to systemic...

Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital...

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer ( Dr Rushabh Kiran Kothari (PI, CRSF group) - Narayana Multispeciality Hospital, Ahmedabad, India )

Vaccine-immunotherapy combo for high risk melanoma: New data on distant...

Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia

Vaccine-immunotherapy combo for high risk melanoma: New data on distant metastasis-free survival ( Prof Muhammad Adnan Khattak - Fiona Stanley Hospital, Perth, Australia )

Next-generation selective RET inhibitor shows initial promise with RET-altered...

Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China

Next-generation selective RET inhibitor shows initial promise with RET-altered solid tumours ( Prof Qing Zhou - Guangdong Provincial People’s Hospital, Guangzhou, China )

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced...

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced rectal cancer ( Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

Osimertinib after surgery significantly improves survival in resected EGFR...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLC ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Ciltacabtagene autoleucel greatly reduces risk of disease progression in...

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

More from ecancer